Fate Therapeutics, Inc. (FATE): Price and Financial Metrics

Fate Therapeutics, Inc. (FATE)

Today's Latest Price: $35.26 USD

1.09 (-3.00%)

Updated Jul 10 4:00pm

Add FATE to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 338 in Biotech

See all "A" rated Strong Buy stocks

FATE Stock Summary

  • Of note is the ratio of Fate Therapeutics Inc's sales and general administrative expense to its total operating expenses; only 10.5% of US stocks have a lower such ratio.
  • FATE's price/sales ratio is 259.34; that's higher than the P/S ratio of 98.45% of US stocks.
  • As for revenue growth, note that FATE's revenue has grown 66.45% over the past 12 months; that beats the revenue growth of 92.02% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Fate Therapeutics Inc, a group of peers worth examining would be PRQR, DNLI, QURE, SYRS, and PRNB.
  • Visit FATE's SEC page to see the company's official filings. To visit the company's web site, go to www.fatetherapeutics.com.
FATE Daily Price Range
FATE 52-Week Price Range

FATE Stock Price Chart Technical Analysis Charts

FATE Price/Volume Stats

Current price $35.26 52-week high $38.52
Prev. close $36.35 52-week low $12.59
Day low $35.14 Volume 712,031
Day high $36.70 Avg. volume 1,122,155
50-day MA $31.72 Dividend yield N/A
200-day MA $23.91 Market Cap 2.74B

Fate Therapeutics, Inc. (FATE) Company Bio

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops programmed cellular immunotherapies for cancer and immune disorders in the United States. The company was founded in 2007 and is based in San Diego, California.

FATE Latest News Stream

Event/TimeNews Detail
Loading, please wait...

FATE Latest Social Stream

Loading social stream, please wait...

View Full FATE Social Stream

Latest FATE News From Around the Web

Below are the latest news stories about Fate Therapeutics Inc that investors may wish to consider to help them evaluate FATE as an investment opportunity.

Fate's IND Application for CAR T Cell Therapy Gets FDA Nod

Fate (FATE) obtains FDA clearance for its IND application for FT819, targeting CD19+ malignancies.

Yahoo | July 10, 2020

Fate Therapeutics on go to advance CAR T candidate FT819 into the clinic

The FDA has signed off on Fate Therapeutics' (FATE) IND to start clinical development of FT819, an off-the-shelf allogeneic chimeric antigen receptor ((CAR)) T-cell therapy targeting CD19+ malignancies.The company says FT819 is the first CAR T therapy derived from a clonal master induced pluripotent stem cell line, one of several...

Seeking Alpha | July 9, 2020

Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy

FT819 CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus Phase 1 Clinical Study will Evaluate FT819.

Yahoo | July 9, 2020

The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) AbbVie Inc (NYSE: ABBV ) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) argenx SE – ADR (NASDAQ: ARGX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (FDA approved the cellulitis drug it had licensed to Endo International PLC (NASDAQ: ENDP )) Cerus Corporation (NASDAQ: CERS ) (announced study results demonstrating that its INTERCEPT Blood System inactivates SARS-CoV-2 in plasma components intended for transfusion) Corvus Pharma...

Benzinga | July 8, 2020

Notable Insider Buys Last Week: Cigna, Fox, Uber And More

Insider buying can be an encouraging signal for potential investors. Some insiders took advantage of a secondary offering last week. Two chief executives also have stepped up to the buy window. Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit. So insider buying can be an encouraging signal for potential investors, particularly during periods of uncertainty. Insiders continued to add shares despite overall market volatility and economic uncertainty. The following are some of the most noteworthy insider purchases reported in the past week. A director at Axis Capital Holdings Limited (NYSE: AXS ) indirectly bought less than 1.35 million shares of this Bermuda-based compa...

Benzinga Feeds | June 20, 2020

Read More 'FATE' Stories Here

FATE Price Returns

1-mo 18.12%
3-mo N/A
6-mo 62.56%
1-year 63.70%
3-year 984.92%
5-year 344.64%
YTD 80.17%
2019 52.53%
2018 109.98%
2017 143.43%
2016 -25.52%
2015 -33.00%

Continue Researching FATE

Here are a few links from around the web to help you further your research on Fate Therapeutics Inc's stock as an investment opportunity:

Fate Therapeutics Inc (FATE) Stock Price | Nasdaq
Fate Therapeutics Inc (FATE) Stock Quote, History and News - Yahoo Finance
Fate Therapeutics Inc (FATE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9571 seconds.